Document Detail


Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation.
MedLine Citation:
PMID:  22953675     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
BACKGROUND AND AIM OF THE STUDY: Aortic regurgitation (AR) is a disease for which there is currently no effective medical treatment. It has been shown previously in an experimental model of AR that the renin-angiotensin-aldosterone system (RAAS) plays a major role, and that medications blocking the RAAS are effective to protect against left ventricular (LV) hypertrophy and also help to maintain a normal systolic function. The role of aldosterone receptor blockers in this disease has never been evaluated. Thus, the effects were studied of the aldosterone receptor blocking agent spironolactone in a model of chronic AR in rats.
METHODS: The effects of a six-month treatment with spironolactone were evaluated in adult Wistar rats with severe AR, compared to sham-operated and untreated AR animals.
RESULTS: Spironolactone treatment decreased the total heart weight. In addition, the LV expression of atrial natriuretic peptide mRNA was decreased by spironolactone treatment, as was the expression of collagen 1 and LOX1 mRNAs. Left ventricular fibrosis was decreased by spironolactone treatment.
CONCLUSION: Spironolactone protected against volume-overload cardiomyopathy in this model of aortic valve regurgitation. The predominant protective effect was a decrease in myocardial fibrosis.
Authors:
Adnane Zendaoui; Dominic Lachance; Elise Roussel; Jacques Couet; Marie Arsenault
Related Documents :
1904965 - Hydrogen peroxide release by mitochondria increases during aging.
1435765 - Detection of ischemia-reperfusion cardiac injury by cardiac muscle chemiluminescence.
24893205 - Epoxyeicosatrienoic acids and cardioprotection: the road to translation.
18468595 - Exogenous hydrogen sulfide postconditioning protects isolated rat hearts against ischem...
24997495 - Cerebrovascular disease in the era of left ventricular assist devices with continuous f...
20812935 - The atria: from morphology to function.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of heart valve disease     Volume:  21     ISSN:  0966-8519     ISO Abbreviation:  J. Heart Valve Dis.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-09-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9312096     Medline TA:  J Heart Valve Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  478-86     Citation Subset:  IM    
Affiliation:
Groupe de Recherche sur les Valvulopathies, Centre de Recherche de l'Institut universitaire de Cardiologie et pneumologie de Québec, Université Laval, Québec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Grant Support
ID/Acronym/Agency:
/MOP-61818//Canadian Institutes of Health Research
Comments/Corrections
Comment In:
J Heart Valve Dis. 2012 Jul;21(4):473-5   [PMID:  22953673 ]
J Heart Valve Dis. 2012 Jul;21(4):476-7   [PMID:  22953674 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rosuvastatin slows the development of diastolic dysfunction in calcific aortic stenosis.
Next Document:  Urgent aortic valve replacement in octogenarians: does an 'urgent' status increase morbidity and mor...